Jump to content

Efruxifermin

Add links
From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Entranced98 (talk | contribs) at 12:14, 28 March 2024 (Importing Wikidata short description: "Experimental drug"). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Efruxifermin
Clinical data
Other namesAKR-001; AMG-876
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem SID
UNII

Efruxifermin (AKR-001) is a fibroblast growth factor 21 (FGF21) analog developed to treat nonalcoholic steatohepatitis and type 2 diabetes.[1][2][3]

References

[edit]
  1. ^ Shao, Weijuan; Jin, Tianru (March 2022). "Hepatic hormone FGF21 and its analogues in clinical trials". Chronic Diseases and Translational Medicine. 8 (1): 19–25. doi:10.1016/j.cdtm.2021.08.005. ISSN 2589-0514. PMC 9126297. PMID 35620160.
  2. ^ Carvalho, Thiago (20 June 2023). "Efruxifermin combined with a GLP-1 receptor agonist reduces liver fat in NASH". Nature Medicine. 29 (8): 1881. doi:10.1038/d41591-023-00055-1. PMID 37340082. S2CID 259210572.
  3. ^ Kaufman, Allegra; Abuqayyas, Lubna; Denney, William S.; Tillman, Erik J.; Rolph, Tim (July 2020). "AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients". Cell Reports Medicine. 1 (4): 100057. doi:10.1016/j.xcrm.2020.100057. PMC 7659583. PMID 33205064.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Efruxifermin&oldid=1215995093"